View Information Collection Request (ICR) Package
Skip to main content
An official website of the United States government
The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Search:
Agenda
Reg Review
ICR
This script is used to control the display of information in this page.
Display additional information by clicking on the following:
All
Brief and OIRA conclusion
Abstract/Justification
Legal Statutes
Rulemaking
FR Notices/Comments
IC List
Burden
Misc.
Common Form Info.
Certification
View Information Collection (IC) List
View Supporting Statement and Other Documents
Please note that the OMB number and expiration date may not have been determined when this Information Collection Request and associated Information Collection forms were submitted to OMB. The approved OMB number and expiration date may be found by clicking on the Notice of Action link below.
View ICR - OIRA Conclusion
OMB Control No:
0910-0616
ICR Reference No:
201412-0910-013
Status:
Historical Active
Previous ICR Reference No:
201109-0910-006
Agency/Subagency:
HHS/FDA
Agency Tracking No:
CBER
Title:
Certification to Accompany Drug, Biological Product, and Device Applications or Submissions
Type of Information Collection:
Extension without change of a currently approved collection
Common Form ICR:
No
Type of Review Request:
Regular
OIRA Conclusion Action:
Approved with change
Conclusion Date:
02/09/2015
Retrieve Notice of Action (NOA)
Date Received in OIRA:
12/30/2014
Terms of Clearance:
Inventory as of this Action
Requested
Previously Approved
Expiration Date
02/28/2018
36 Months From Approved
02/28/2015
Responses
20,712
0
19,353
Time Burden (Hours)
7,119
0
6,881
Cost Burden (Dollars)
0
0
0
Abstract:
This ICR collects information submitted to FDA with new investigational and marketing applications/submissions and certain additional submissions to such applications for human drugs, biological products, and devices. Respondents submit information as provided under statutory requirements that sponsors/applicants/submitters have complied with the certification provisions in the law with regard to any applicable clinical trials referenced in the investigational or marketing applications/submissions with which the certification is submitted. FDA has developed Form FDA 3674 to facilitate this certification and assist with correlating the clinical trials contained in the applications/submissions to FDA with the information contained in the ClinicalTrials.gov data bank.
Authorizing Statute(s):
US Code:
42 USC 282
Name of Law: Public Health Service Act
PL:
Pub.L. 110 - 85 VIII
Name of Law: Food and Drug Administration Amendments Act of 2007
Citations for New Statutory Requirements:
None
Associated Rulemaking Information
RIN:
Stage of Rulemaking:
Federal Register Citation:
Date:
Not associated with rulemaking
Federal Register Notices & Comments
60-day Notice:
Federal Register Citation:
Citation Date:
79 FR 38905
07/09/2014
30-day Notice:
Federal Register Citation:
Citation Date:
79 FR 75819
12/19/2014
Did the Agency receive public comments on this ICR?
No
Number of Information Collection (IC) in this ICR:
13
IC Title
Form No.
Form Name
BE Supplements/Amendments
FDA 3674
Certification of Compliance
Clinical Amendments to Marketing Applications
FDA 3674
Certification of Compliance
Clinical Amendments to Marketing Applications
FDA 3674
Certification of Compliance
Clinical Protocol Amendments (IND)
FDA 3674
Certification of Complicance
Clinical Protocol Amendments (IND)
FDA 3674
Certification of Compliance
Efficacy Supplements/Resubmissions
FDA 3674
Certification of Compliance
Efficacy Supplements/Resubmissions (BLA Only)
3674
Certification of Compliance
New Applications (IND)
FDA 3674
Certification of Compliance
New Applications (IND)
FDA 3674
Certification of Compliance
New Marketing Applications (includes PMAs, HDEs, Supplements and 510(k)s expected to contain clinical data)
FDA 3674
Certification of Compliance
New Marketing Applications/Resubmissions (NDA/BLA)
FDA 3674
Certification of Compliance
New Marketing Applications/Resubmissions (NDA/BLA)
FDA 3674
Certification of Compliance
Original Applications
FDA 3674
Certification of Compliance
ICR Summary of Burden
Total Approved
Previously Approved
Change Due to New Statute
Change Due to Agency Discretion
Change Due to Adjustment in Estimate
Change Due to Potential Violation of the PRA
Annual Number of Responses
20,712
19,353
0
0
1,359
0
Annual Time Burden (Hours)
7,119
6,881
0
0
238
0
Annual Cost Burden (Dollars)
0
0
0
0
0
0
Burden increases because of Program Change due to Agency Discretion:
No
Burden Increase Due to:
Burden decreases because of Program Change due to Agency Discretion:
No
Burden Reduction Due to:
Short Statement:
The increase in burden reflects a change in the overall number of research and marketing applications/submissions received by FDA since the previous estimate.
Annual Cost to Federal Government:
$0
Does this IC contain surveys, censuses, or employ statistical methods?
No
Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002?
No
Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]?
No
Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]?
No
Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)?
No
Is this ICR related to the Pandemic Response?
Uncollected
Agency Contact:
Ila Mizrachi 301 796-7726 ila.mizrachi@fda.hhs.gov
Common Form ICR:
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(a) It is necessary for the proper performance of agency functions;
(b) It avoids unnecessary duplication;
(c) It reduces burden on small entities;
(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;
(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;
(f) It indicates the retention periods for recordkeeping requirements;
(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.
(i) It uses effective and efficient statistical survey methodology (if applicable); and
(j) It makes appropriate use of information technology.
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
Certification Date:
12/30/2014
Something went wrong when downloading this file. If you have any questions, please send an email to risc@gsa.gov.